XNX-C010Ds / Xylonix - LARVOL DELTA

[VIRTUAL] Anti-tumor effects from simultaneous cancer and TAM targeting by 010DS-Zn (AACR 2021) - "Collectively, 010DS-Zn presents new cancer immunotherapeutic potentials for enabling previously inaccessible 2-combination therapies for targeting 3 layers of immune-evasion: Tregs, TAM, and MDSC. Furthermore, its ability to directly clear M2-like macrophages presents opportunities-worth-investigation for treating the M2-like macrophage-driven severe SARS-CoV-2 autoimmune syndromes or its post-recovery heart-damages."

Breast Cancer • Hematological Malignancies • Oncology • Solid Tumor • PARP1

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages (PRNewswire) - "Xylonix...has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers....Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells. This resulted in tumour suppression in animal studies. It also demonstrated consistent anti-cancer activity in 53 human patient-derived cancers tested ex vivo."

Preclinical • Oncology